Amgen, Inc. could more than double the patient base for Uplizna (inebilizumab), currently approved to treat neuromyelitis optica spectrum disorder (NMOSD), with new Phase III data showing the antibody therapy can also treat patients with the rare immune-mediated disease immunoglobulin G4-related disease (IgG4-RD).
Amgen Phase III Data Could Add Second Indication To Uplizna’s Label
Amgen’s study shows an 87% risk-reduction for IgG4-related disease flares, which can exacerbate the rare disorder and lead to irreversible organ failure. A US filing is planned.
